Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Augusto Caballero-Robles

Endocrinology, Diabetes & Metabolism Boston, MA Medical Doctor

NPI 1144336918 CMS profile 233535

Joslin Diabetes Center, One Joslin Place, Boston, MA 02215

Open in the dashboard

General payments

$149,526

57 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Augusto Caballero-Robles of Boston, MA is reported in the CMS Open Payments database as having received $149,526 across 57 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $3,723 4
2023 General $63 1
2021 General $11,655 7
2020 General $28,156 8
2019 General $105,930 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Augusto Caballero-Robles
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Augusto Caballero-Robles were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Augusto Caballero-Robles Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $105,930 $494 $123–$2,253 $163
2020 $28,156 $335 $85–$1,841 $114
2021 $11,655 $398 $88–$1,981 $132
2022 $0 $364 $88–$1,568 $149
2023 $63 $420 $113–$1,614 $160
2024 $3,723 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boehringer Ingelheim MENA (Scientific Office) FZ-LLC $72,214 10 payments
  2. Eli Lilly and Company $26,617 12 payments
  3. Boehringer Ingelheim Saudi Arabia Trading $11,765 1 payment
  4. Merck Sharp & Dohme Corporation $9,226 12 payments
  5. Boehringer Ingelheim Do Brasil Quimica e Farmaceutical Ltda. $8,140 5 payments
  6. Takeda Pharmaceuticals International, Inc. $7,500 1 payment
  7. E.R. Squibb & Sons, L.L.C. $5,046 11 payments
  8. Sanofi-Aventis U.S. LLC $3,526 1 payment
  9. Intercept Pharmaceuticals, Inc. $2,100 1 payment
  10. Boehringer Ingelheim South Africa (Pty) Ltd $1,850 1 payment
  11. Other $1,543 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $91,980 15 payments
  2. Consulting Fee $36,369 7 payments
  3. Travel and Lodging $17,576 16 payments
  4. Honoraria $2,100 1 payment
  5. Food and Beverage $1,501 18 payments
Products named General payments · program years 2019–2024
  1. JARDIANCE $81,979 10 payments
  2. Kazano $7,500 1 payment
  3. Nesina $7,500 1 payment
  4. Oseni $7,500 1 payment
  5. ORENCIA $5,046 11 payments
  6. SYNJARDY $1,850 1 payment
  7. Ozempic $63 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

57 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record